108 results about "Muc1 Mucin" patented technology

The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody fragments, where the antibodies and antibody fragments recognize extracellular epitopes of plasma membrane proteins that are not released into the extracellular fluid, and to methods for the detection, monitoring and treatment of malignancies such as breast cancer and ovarian cancer using the antibodies, antibody fragments and conjugates.

The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.

This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.

The invention provides a method for detection of a malignancy in a specimen of bodily fluid. The method comprises contacting the specimen with at least two antigens selected from the group consisting of p53, IGFBP2, Topo2α, cathepsin D, cyclin B, cyclin D1, MUC1, HER-2 / neu and CEA. The method further comprises incubating the specimen and the antigen for a duration and under conditions that are sufficient for the formation of immunocomplexes; and detecting the presence or absence of immunocomplex formation between the antigens and antibodies specific for the antigens in the specimen, thereby determining the presence or absence of the malignancy. Also provided is a method for monitoring the effectiveness of cancer therapy related to a malignancy in a warm-blooded animal, a method for distinguishing between Stage I and Stage II colorectal cancer in a specimen of bodily fluid.

The invention provides therapeutic compositions comprising binding agents that specifically bind to tumor-associated MUC-1 and reduce, reverse or prevent their effects in cancer. More particularly, the invention provides therapeutic compositions that comprise a binding agent that can specifically bind to an epitope that comprises both peptide and carbohydrate on such tumor-associated MUC-1. The invention further provides methods for the use of such therapeutic compositions in the treatment of cancer.The invention also provides methods for therapeutically treating a mammal bearing a tumor comprising administering to the mammal an effective amount of a therapeutic composition consisting essentially of a binding agent that specifically binds to an epitope of tumor-associated MUC1, wherein the mammal generates an immune response that comprises an antibody that specifically binds to an epitope of tumor-associated MUC1 that is different from the epitope of tumor associated MUC1 that is specifically bound by the binding agent.

Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and / or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.

The present invention provides for improved vectors for use in gene therapy. Utilizing the cancer specific DF3 / MUC1 promoter to drive a replication essential gene, vectors are made conditionally replication-competent, permitting wider infection and expression of tumor cells. In addition, therapeutic genes and adjunct therapies further increase anti-tumor efficacy.

The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.

The present application describes a method for inducing or maintaining pluripotency in a cell by contacting the cell with a biological or chemical species that increases MUC1* activity.

Recombinant pox viruses capable of expressing an immunogenic fragment of the MUC1 tumor-associated antigen are disclosed. The recombinant viruses can be used as vaccines to prevent the establishment of or treat tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The vaccines can be provided as an admixture comprising: (1) a recombinant pox virus encoding the immunogenic fragment of the MUC1 tumor-associated antigen, and (2) a recombinant pox virus encoding a T-cell co-stimulatory factor. The vaccine admixture can be used, e.g., to prevent establishment of tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The MUC1 specific cytotoxic T-cells can be isolated and expanded and used in a method for treating a host having a tumor expressing MCU1 positive tumor cells.

A glycolipopeptide comprising at least one disease-associated epitope, and characterized by at least one lipidated interior amino acid or by the presence of a MUC1 epitope, may be used in a vaccine, preferably in conjunction with a liposome.

The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and / or killing a cancer cell using a receptor that is similar to or is a T cell receptor

An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.

Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT. Also disclosed are methods of using and identifying such ligands.

The present application discloses methods of detecting and treating cancer which express MUC1 aberrantly.

An anticancer vaccine of recombinant human MOC1-MBP fusion protein is disclosed, in which MBP is used as its adjuvant. The MBP gene and MUC1 gene are fused together. The MBP substituted for other fusion protein to induce CTL reaction. The pMAL-P2 is the carrier for effectively expressing maltose fusion protein. The serial repetitive sequence of MUC1 is inserted to downstream of malE gene.

The invention relates to a chimeric antigen receptor, nucleic acid coding the chimeric antigen receptor, a construct containing nucleic acid, an expression vector, a transformed cell and pharmacy application of the chimeric antigen receptor, nucleic acid coding the chimeric antigen receptor, the construct containing nucleic acid, the expression vector and the transformed cell. The chimeric antigen receptor comprises at least one extracellular domain, an optional transmembrane domain and at least one intracellular signal transduction domain, wherein each extracellular domain comprises an SC-FV fragment derived from a heavy chain and a light chain of an MUC1 or PSCA specific monoclonal antibody or gene modification which is conducted on the basis of the domain and an optimal signal peptide, and each intracellular signal transduction domain comprises a immune costimulatory signal combination. According to the transformed cell, the capacity of the transformed cell for killing solid tumor cells in vitro and in vivo is significantly improved and is higher than that of a conventional chimeric antigen receptor with a structure of the second generation.

New synthetic Lipid-A analogs based on monosaccharide (1) and disaccharide (2) derivatives were designed and prepared in the present invention. Both structures (1) and (2) incorporate novel lipid structures (3) and (4) that are not found in nature. Also, novel disaccharide Lipid-A structures (2) that incorporate novel contingents of uniform lipids and where R1, R4 and R5 are the same substitution group of structure (III) were synthesized. Liposome formulations containing totally synthetic components such as synthetic Lipid-A and synthetic lipopeptide derived from tumor-associated MUC1 mucin are described along with their therapeutic utility. Comparative test results of immunostimulating properties and toxicity of Lipid-A analogs (1) and (2) are included.

The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.

The object of the present invention is to provide antibodies specific to cancer cells that do not bind to normal cells. The inventors of the present invention found that: using 2,3ST glycopeptides as antigens to immunize animals, the antibodies obtained unexpectedly, significantly and specifically recognize cancer-specific sugar chains, and then can recognize and kill cancer cells expressing such Cancer cells with specific sugar chains of MUC1, thereby solving the above-mentioned problems. The present invention provides an antibody, an antigen-binding fragment thereof, or a MUCl-binding molecule, which is, for example, 100-fold or more specific for a cancer-associated structure of MUCl as compared to a normal tissue-associated structure of MUCl.

Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and / or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).

The invention provides an Anti-MUC1 CAR-T cell and its preparation method and application. The Anti-MUC1 CAR-T cell expresses a SCFV-IgD-CD28-OX40-CD3 zeta fusion protein in the T cell. In the SCFV-IgD-CD28-OX40-CD3 zeta fusion protein, the SCFV is used to bind to the MUC1 protein. The amino acid sequence of SCFV is a first sequence. The cell is obtained by ornament and modification of the T cell, can specifically recognize and kill adenocarcinoma and is suitable for prevention and treatment on the corresponding tumor diseases.

The present invention pertains to anti-mucin antibodies having improved antigen binding and / or recognition properties as well as a method for improving the antigen binding and / or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.

The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.

The invention relates to an MUC1 protein nucleic acid aptamer, a complex, a composition and purposes thereof. The invention particularly relates to a nucleic acid aptamer specifically combined with an MUC1 protein, and the sequence of the aptamer is shown as SEQ ID NO.9. The complex is formed by the fact that the MUC1 protein is specifically combined with the nucleic acid aptamer and chemotherapy drugs, or the MUC1 protein, the nucleic acid aptamer and the chemotherapy drugs are wrapped in a nanometer particle. The composition comprises the complex. The nucleic acid aptamer, the complex and the composition have the purpose of tumor resistance and the purpose of tumor targeted radiography.

The invention provides a series of compositions, methods, kits, articles and species associated primarily with the diagnosis and / or treatment of cell proliferation, specifically cancer. Cell proliferation associated with aberrant expression of MUC1 is particularly focused upon. Mechanisms associated with MUC1 cell proliferation are discussed.

The invention provides method of treating cancers that express MUC1 by the administration of PI3-K inhibitors in combination with MUC1-directed cancer therapies. The PI3-K inhibition may advantageously be combined with peptides that inhibit MUC1 oligomerization, or further with other standard anticancer therapies such as chemo-, radio- and surgical therapies.